Prelude Capital Management’s Nuvation Bio NUVB Stock Holding History

Prelude Capital Management’s Portfolio NUVB Stock Details NUVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$58.3K	Buy	+13,583	New	+$75.7K	﹤0.01%	1114
2024 Q3	–	Sell	-36,440	Closed	-$106K	–	1476
2024 Q2	$106K	Sell	36,440 -12,760	-26%	-$38.9K	0.01%	1093
2024 Q1	$179K	Buy	+49,200	New	+$94.5K	0.01%	1131
2023 Q4	–	Sell	-32,932	Closed	-$44.1K	–	1261
2023 Q3	$44.1K	Sell	32,932 -32,572	-50%	-$54.2K	﹤0.01%	1053
2023 Q2	$118K	Sell	65,504 -8,271	-11%	-$14.1K	0.01%	911
2023 Q1	$122K	Sell	73,775 -2,429	-3%	-$4.92K	0.01%	933
2022 Q4	$146K	Buy	76,204 +23,500	+45%	+$47.5K	0.01%	1018
2022 Q3	$118K	Buy	+52,704	New	+$150K	﹤0.01%	1152
2021 Q2	–	Sell	-12,762	Closed	-$133K	–	1864
2021 Q1	$133K	Buy	+12,762	New	+$143K	﹤0.01%	1389

Other funds holding NUVB

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

DFO

Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Prelude Capital Management's NUVB Position: Q1 2026 in Review

Prelude Capital Management opened a new position in Nuvation Bio (NUVB) in Q1 2026: 13,583 shares worth $58.3K. The stake represents ﹤0.01% of the portfolio and ranks #1114 among its holdings. This is a return to the name: Prelude Capital Management previously reported a position in NUVB as recently as Q2 2024.

Prelude Capital Management first reported a position in NUVB in Q1 2021 and has held it in 9 quarters since. The position peaked at $179K in Q1 2024. 231 funds tracked by Wall St. Rank hold NUVB as of Q1 2026.

Prelude Capital Management held 13,583 shares of Nuvation Bio worth $58.3K as of Q1 2026.
Nuvation Bio was a new Prelude Capital Management position in Q1 2026.
Nuvation Bio made up ﹤0.01% of Prelude Capital Management's portfolio in Q1 2026, its #1114 holding.
Prelude Capital Management first reported a position in Nuvation Bio in Q1 2021 and has held it in 9 quarters since.
Prelude Capital Management's Nuvation Bio position peaked at $179K in Q1 2024.
231 funds tracked by Wall St. Rank held Nuvation Bio as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.